137 related articles for article (PubMed ID: 10627636)
21. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens.
Deininger M; Pönisch W; Krahl R; Leiblein S; Edel E; Lange T; Fiedler F; Freund M; Franke A; Pasold R; von Grünhagen U; Herold M; Dölken G; Hoffmann FA; Uhle R; Schultze W; Steglich J; Schwarzer A; Richter P; Winkelmann C; Kettner E; Dachselt K; Subert R; Schwalbe E; Doepper J; Helbig W; Niederwieser D;
Bone Marrow Transplant; 2001 Jun; 27(11):1125-32. PubMed ID: 11551022
[TBL] [Abstract][Full Text] [Related]
23. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
[TBL] [Abstract][Full Text] [Related]
24. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
[TBL] [Abstract][Full Text] [Related]
25. Collection of Ph-negative progenitor cells from Ph+ CML patients in complete cytogenetic remission after long-term interferon-alpha therapy.
Russo D; Martinelli G; Montefusco V; Amabile M; Rosti G; Marin L
Haematologica; 1999 Oct; 84(10):953-5. PubMed ID: 10509048
[No Abstract] [Full Text] [Related]
26. Peripheral blood stem cell collection in children with acute leukemia: effectiveness of the 'DIAVE' mobilizing regimen.
Balduzzi A; Perseghin P; Dassi M; Bonanomi S; Rovelli A; Gaipa G; Biondi A; Uderzo C
Bone Marrow Transplant; 2002 Oct; 30(7):413-6. PubMed ID: 12368951
[TBL] [Abstract][Full Text] [Related]
27. Autografting Ph-negative blood precursor cells in chronic myeloid leukaemia.
Frassoni F; Giordano D; Podestà M; Piaggio G; Benvenuto F; Pitto A; Figari O; Dejana A; Lerma E; Vassallo F; Sessarego M; Carella A
Bone Marrow Transplant; 1996 May; 17 Suppl 3():S59-62. PubMed ID: 8769704
[TBL] [Abstract][Full Text] [Related]
28. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia.
Carella AM; Dejana A; Lerma E; Podestà M; Benvenuto F; Chimirri F; Parodi C; Sessarego M; Prencipe E; Frassoni F
Br J Haematol; 1996 Oct; 95(1):127-30. PubMed ID: 8857949
[TBL] [Abstract][Full Text] [Related]
29. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
[TBL] [Abstract][Full Text] [Related]
30. EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.
Hart C; Grassinger J; Andreesen R; Hennemann B
Bone Marrow Transplant; 2009 Feb; 43(3):197-206. PubMed ID: 18806833
[TBL] [Abstract][Full Text] [Related]
31. ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience.
Jerkeman M; Leppä S; Kvaløy S; Holte H
Eur J Haematol; 2004 Sep; 73(3):179-82. PubMed ID: 15287915
[TBL] [Abstract][Full Text] [Related]
32. Therapy of acute phase chronic myelogenous leukemia with intensive chemotherapy, blood cell autotransplant and cyclosporine A.
Carella AM; Gaozza E; Raffo MR; Carlier P; Frassoni F; Valbonesi M; Lercari G; Sessarego M; Defferrari R; Guerrasio A
Leukemia; 1991 Jun; 5(6):517-21. PubMed ID: 1676080
[TBL] [Abstract][Full Text] [Related]
33. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
34. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
[TBL] [Abstract][Full Text] [Related]
35. [Autologous hemopoietic stem cell transplantation in treatment of chronic myelogenous leukemia].
Sacha T; Hawrylecka D; Skotnicki AB
Przegl Lek; 1999; 56 Suppl 1():62-6. PubMed ID: 10494185
[TBL] [Abstract][Full Text] [Related]
36. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
37. [Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia].
Boqué C; Grañena A
Sangre (Barc); 1998 Apr; 43(2):155-63. PubMed ID: 9656777
[No Abstract] [Full Text] [Related]
38. High-dose hydroxyurea plus G-CSF mobilize BCR-ABL-negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of hematopoietic regeneration.
Petzer AL; Hochenburger E; Haun M; Duba HCh; Grünewald K; Hoflehner E; Sill H; Linkesch W; Gastl G; Gunsilius E
J Hematother Stem Cell Res; 2002 Apr; 11(2):293-300. PubMed ID: 11983100
[TBL] [Abstract][Full Text] [Related]
39. Mobilization kinetics of peripheral blood progenitor cells after IAPVP-16 salvage chemotherapy plus G-CSF in lymphoproliferative disorders.
Altés A; López R; Martino R; Martinez C; Cabezudo E; Muñoz L; Santamaría A; Perea G; Briones J; Salar A; Sureda A; Brunet S; Madoz P; Sierra J
Bone Marrow Transplant; 2000 Jul; 26(2):127-32. PubMed ID: 10918421
[TBL] [Abstract][Full Text] [Related]
40. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF.
Gómez-Espuch J; Moraleda JM; Ortuño F; Lozano ML; Ayala F; Vallejo C; de Arriba F; Vicente V
Bone Marrow Transplant; 2000 Feb; 25(3):231-5. PubMed ID: 10673692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]